Compare FMST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMST | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | 2 | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 36.5M |
| IPO Year | N/A | 2024 |
| Metric | FMST | BOLD |
|---|---|---|
| Price | $1.52 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 82.7K | 67.2K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $0.96 |
| 52 Week High | $4.57 | $1.68 |
| Indicator | FMST | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 45.14 |
| Support Level | $1.49 | $1.12 |
| Resistance Level | $1.94 | $1.53 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 26.36 | 15.77 |
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.